ICARe-HF-accreditatie correleert met betere richtlijntherapie bij hartfalen — GRASP-HF
De prospectieve GRASP-HF-cohortstudie (n=10.936) vergeleek de implementatie van richtlijntherapie tussen hartfalencentra met en zonder ICARe-HF-accreditatie. Centra met accreditatie gaven vaker quadruple therapy (OR 1,73) en gebruikten meer ARNI’s en SGLT2-remmers, vooral bij HFrEF. Hoewel de ruwe sterfelijkheid lager was, verdween dit verschil na correctie voor confounders. De bevindingen onderstrepen de meerwaarde van gestructureerde kwaliteitsprogramma’s voor het optimaliseren van medicamenteuze hartfalenbehandeling in de dagelijkse zorg.
Abstract (original)
BACKGROUND: The Global Registries and Surveys Programme-Heart Failure (GRASP-HF) is a prospective, multicentre, international observational study assessing implementation of the 2021/2023 ESC-HF-Guidelines. GRASP-HF is aligned with the Improving Care through Accreditation and Recognition in Heart Failure (ICARe-HF) programme, which links centre-characteristics with guideline-implementation performance. AIMS: To compare baseline characteristics, guideline-directed-medical-therapy (GDMT) implementation, and in-hospital outcomes between GRASP-HF patients managed in centres participating or not participating in the ICARe-HF programme. METHODS: GRASP-HF patients were stratified by ICARe-HF participation, clinical settings, acute (AHF) vs chronic HF (CHF) and ejection fraction (EF) subtypes. Hierarchical multivariable logistic regression models evaluated associations with quadruple therapy implementation and in-hospital mortality. RESULTS: Among 10,936 patients (63.3% CHF, 36.7% AHF), patients from ICARe-HF participating centres (51.3%) were older, more comorbid but with less severe congestion. In both CHF and AHF, ICARe-HF centres demonstrated greater GDMT utilization, particularly angiotensin receptor-neprilysin inhibitors and sodium-glucose-cotransporter-2 inhibitors. In HFrEF, quadruple therapy was more frequently implemented (47% vs 40% in CHF; 27% vs 24% at AHF discharge) and remained associated with ICARe-HF participation after adjustment, Odd Ratio (OR) =1.73, 95% Confidence Interval (CI) :1.17-2.55. Target doses remained suboptimal, particularly after AHF. Although crude in-hospital mortality was lower in ICARe-HF centres (2.3% vs 5.5%), this association was attenuated after multivariable adjustment (OR=0.87, 95% CI:0.48-1.56). CONCLUSIONS: Participation in the ICARe-HF programme was associated with more comprehensive implementation of contemporary GDMT, particularly in HFrEF. The association with in-hospital mortality was attenuated after adjustment and should be considered exploratory.
Dit artikel is een samenvatting van een publicatie in European journal of heart failure. Voor het volledige artikel, alle details en referenties verwijzen wij u naar de oorspronkelijke bron.
Lees het volledige artikelDOI: 10.1093/ejhf/xuag317
Wilt u op de hoogte blijven?
Gratis: de maandelijkse nieuwsbrief met het nieuwsoverzicht, en de site afgestemd op uw vakgebied.